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In recent decades, long-term use of hormone replacement
therapy (HRT) has been widely and heavily promoted as a
prophylaxis against heart disease and other illnesses.  Millions
of women have taken these medications based on their
physicians’ recommendations, which were made despite the
absence of data from clinical trials demonstrating benefit.
Belief in a protective effect of HRT against heart disease was
based on the results of observational studies,1 the effect of HRT
on selected lipid and other parameters,2 and the widely held
but unsubstantiated belief that endogenous female hormones
protect women against coronary heart disease.3,4
Data from randomised trials, the gold standard for assessing
the potential protective effect of a medication, are now
available on the effect of oestrogen taken with a progestin.5-7
The largest and most definitive trial is the Women’s Health
Initiative (WHI),7 in which women with a uterus were
randomised to take placebo or oestrogen together with
progestin, and women with hysterectomies were randomised
to placebo or oestrogen alone.  The oestrogen-with-progestin
arm of the trial was stopped after 5.2 years rather than the
planned 8.5 years because of greater risk than benefit in the
women taking oestrogen with progestin.   The increased
incidence of breast cancer, venous thromboembolism and
stroke, and decreased incidence of colon cancer and fractures in
users of oestrogen with progestin in the WHI was in agreement
with results of observational studies, but the increased
incidence of coronary heart disease in HRT users was in
conflict with much of the observational data.  
The WHI findings on heart disease seem particularly difficult
for some to accept, but they do not stand alone.  A meta-
analysis of small randomised trials8 also found an increased
risk in users, and the Heart and Estrogen/Progestin
Replacement Study (HERS) trial found no overall protective
effect of HRT and an increased risk in the first year of use.5
Nonetheless, recent comments in the SAMJ indicate an
unwillingness to accept that these results are valid9 and to give
up the belief that some oestrogens and progestins must be
protective against coronary heart disease or that the benefit/
risk ratio for HRT will become favourable if other outcomes are
factored in.10
In a recent article in the SAMJ9 Cheifitz presented an analysis
of changes in disease incidence from year to year in the WHI
and argued that they indicate no major impact in the final 2
years.  Cheifitz’s analysis is incorrect.  As in any well-designed
trial, ‘stopping’ rules were devised at the start so that the trial
would be ended prematurely if there was evidence of benefit
or adversity beyond some defined boundary.  After 5.2 years
there was clear evidence in the oestrogen-plus-progestin arm of
greater harm than benefit — the increase in a ‘global index’ of
disease occurrence was statistically significant, and the
incidence of breast cancer, coronary heart disease, stroke and
venous thromboembolism exceeded the decreases in the
incidence of colon cancer and fractures.  The breast cancers
among women on HRT were more advanced than those among
women on placebo.11 No randomised data are available on
survival, but a recent follow-up study of a million women in
the UK12 found increased breast cancer mortality in oestrogen
users compared with non-users.
In his article Cheifitz suggested that the WHI results are
invalid because some women used HRT previously, some
women changed their use during the trial (e.g. discontinuation
of HRT use), and the analysis of the data was according to
intention to treat.9 None of these criticisms stands up.  Owing
to the randomisation, the prevalence of previous HRT use was
closely similar among the HRT users and placebo users;
therefore previous HRT use could not have distorted the
results.  Indeed, inclusion of women who used HRT before the
trial allowed for analyses according to previous use, which
indicated that breast cancer incidence in the oestrogen-with-
progestin users who had used HRT previously was greater
than that among oestrogen-with-progestin users who had no
previous use.  Intention to treat is the correct analysis for
randomised trials.  Changes in drug use during the trial are
likely to have resulted in underestimation of the effects of use,
not in the creation of spurious associations, as indicated by
subanalyses carried out by the WHI investigators.7
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In a recent SAMJ editorial Sonnendecker and de Villiers10
suggested that the WHI may have failed to find a protective
cardiovascular effect of HRT because the participants may have
been at higher risk of heart disease from HRT because of
previous risk factors or cardiovascular disease. However, the
women in the trial were typical of postmenopausal women
aged 50 - 79 years in the USA and also similar to women in
many of the observational studies that suggested a protective
effect of HRT.1,7
Cheifitz9 suggested that younger women, aged 45 - 55 years,
who have not already developed atherosclerosis would receive
cardiovascular protection from HRT.  Even if this were so, there
is no reason to believe that younger women would not also be
at increased risk of breast cancer, venous thromboembolism,
stroke and other illnesses caused by HRT use through the same
mechanisms operating in older women.  
Sonnendecker and Villiers10 suggested that the benefit-risk
equation will not be complete until randomised data are
available on the effects of HRT on the brain and dementia.
Results from randomised trials have now been published and
indicate no benefit.  The HERS trial13 found that quality of life
among women without menopausal symptoms is poorer
among users of HRT than among users of placebo.   The WHI
study suggests that the incidence of dementia was increased in
users relative to placebo.14,15 These findings go against the oft-
made suggestions that quality of life and brain function are
improved by the use of HRT.  
Sonnendecker and de Villiers10 suggested that other
oestrogens and progestins might have a more favourable
benefit-risk profile and that assessment of their effects should
be a research priority.  The most compelling data on the effects
of different oestrogens and progestins comes from the Million
Women Study.12 This study found that the adverse effect of
HRT on breast cancer incidence differed little according to the
type of oestrogen or progestin, the dose, or the route of
administration.  
Given the millions of women around the world who have
taken HRT, these drugs are responsible for the occurrence of
thousands of cases of illness and death.   Many effective and
safe methods for disease prevention are readily available.  For
example, treatment of hypertension and diabetes, smoking
cessation, and weight loss decrease the incidence of coronary
heart disease without increasing the risk of other illnesses.  It is
not necessary or justified to cause breast cancer and other
serious diseases in women who are essentially healthy in order
to decrease the risk of some other disease.   
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